MYC
Summary: This gene is a proto-oncogene and encodes a nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. The encoded protein forms a heterodimer with the related transcription factor MAX. This complex binds to the E box DNA consensus sequence and regulates the transcription of specific target genes. Amplification of this gene is frequently observed in numerous human cancers. Translocations involving this gene are associated with Burkitt lymphoma and multiple myeloma in human patients. There is evidence to show that translation initiates both from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site, resulting in the production of two isoforms with distinct N-termini. [provided by RefSeq, Aug 2017].
| Name | OMIM ID | Ensembl ID | HGNC ID | PHARMGKB ID | Map Location |
|---|---|---|---|---|---|
| MYC proto-oncogene, bHLH transcription factor | MIM:190080 | Ensembl:ENSG00000136997 | HGNC:HGNC:7553 | PA31353 | 8q24.21 |
GO terms in MYC
| Term Type | Evidence Type | GO Term ID | GO Des. |
|---|---|---|---|
| MF | IDA | GO:0000978 | RNA polymerase II proximal promoter sequence-specific DNA binding |
| MF | IMP | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | ISA | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | ISM | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | NAS | GO:0000981 | RNA polymerase II transcription factor activity, sequence-specific DNA binding |
| MF | IDA | GO:0001077 | transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding |
| MF | ISS | GO:0003677 | DNA binding |
| MF | TAS | GO:0003677 | DNA binding |
| MF | IDA | GO:0003700 | DNA-binding transcription factor activity |
| MF | IPI | GO:0005515 | protein binding |
| MF | IPI | GO:0008134 | transcription factor binding |
| MF | IPI | GO:0033613 | activating transcription factor binding |
| MF | IDA | GO:0044877 | protein-containing complex binding |
| MF | IEA | GO:0046983 | protein dimerization activity |
| MF | IPI | GO:0070491 | repressing transcription factor binding |
| MF | IDA | GO:0070888 | E-box binding |
| CC | IMP | GO:0000790 | nuclear chromatin |
| CC | IDA | GO:0005634 | nucleus |
| CC | IDA | GO:0005654 | nucleoplasm |
| CC | TAS | GO:0005654 | nucleoplasm |
| CC | IDA | GO:0005730 | nucleolus |
| CC | IDA | GO:0032991 | protein-containing complex |
| BP | TAS | GO:0000082 | G1/S transition of mitotic cell cycle |
| BP | IDA | GO:0000122 | negative regulation of transcription by RNA polymerase II |
| BP | IMP | GO:0000165 | MAPK cascade |
| BP | ISS | GO:0001658 | branching involved in ureteric bud morphogenesis |
| BP | ISS | GO:0002053 | positive regulation of mesenchymal cell proliferation |
| BP | NAS | GO:0006112 | energy reserve metabolic process |
| BP | IDA | GO:0006338 | chromatin remodeling |
| BP | TAS | GO:0006357 | regulation of transcription by RNA polymerase II |
| BP | IEA | GO:0006366 | transcription by RNA polymerase II |
| BP | IDA | GO:0006879 | cellular iron ion homeostasis |
| BP | IDA | GO:0006974 | cellular response to DNA damage stimulus |
| BP | IDA | GO:0007050 | cell cycle arrest |
| BP | TAS | GO:0007219 | Notch signaling pathway |
| BP | IDA | GO:0008284 | positive regulation of cell proliferation |
| BP | IDA | GO:0010332 | response to gamma radiation |
| BP | IDA | GO:0010468 | regulation of gene expression |
| BP | IDA | GO:0010628 | positive regulation of gene expression |
| BP | IGI | GO:0010628 | positive regulation of gene expression |
| BP | NAS | GO:0015671 | oxygen transport |
| BP | TAS | GO:0016579 | protein deubiquitination |
| BP | TAS | GO:0019221 | cytokine-mediated signaling pathway |
| BP | IMP | GO:0032204 | regulation of telomere maintenance |
| BP | ISS | GO:0032873 | negative regulation of stress-activated MAPK cascade |
| BP | IDA | GO:0032986 | protein-DNA complex disassembly |
| BP | IEP | GO:0034644 | cellular response to UV |
| BP | IDA | GO:0035690 | cellular response to drug |
| BP | IEP | GO:0042493 | response to drug |
| BP | ISS | GO:0043066 | negative regulation of apoptotic process |
| BP | IDA | GO:0043280 | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process |
| BP | TAS | GO:0044346 | fibroblast apoptotic process |
| BP | IMP | GO:0045656 | negative regulation of monocyte differentiation |
| BP | IDA | GO:0045893 | positive regulation of transcription, DNA-templated |
| BP | ISS | GO:0045893 | positive regulation of transcription, DNA-templated |
| BP | IDA | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IMP | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | TAS | GO:0045944 | positive regulation of transcription by RNA polymerase II |
| BP | IDA | GO:0048146 | positive regulation of fibroblast proliferation |
| BP | IMP | GO:0048146 | positive regulation of fibroblast proliferation |
| BP | IDA | GO:0048147 | negative regulation of fibroblast proliferation |
| BP | IDA | GO:0050679 | positive regulation of epithelial cell proliferation |
| BP | IDA | GO:0051276 | chromosome organization |
| BP | IDA | GO:0051782 | negative regulation of cell division |
| BP | ISS | GO:0051973 | positive regulation of telomerase activity |
| BP | IDA | GO:0060070 | canonical Wnt signaling pathway |
| BP | IDA | GO:0070371 | ERK1 and ERK2 cascade |
| BP | TAS | GO:0070848 | response to growth factor |
| BP | IDA | GO:0071456 | cellular response to hypoxia |
| BP | ISS | GO:0090096 | positive regulation of metanephric cap mesenchymal cell proliferation |
| BP | TAS | GO:1904837 | beta-catenin-TCF complex assembly |
| BP | IMP | GO:2000573 | positive regulation of DNA biosynthetic process |
| BP | IDA | GO:2001022 | positive regulation of response to DNA damage stimulus |
Gene expression in normal tissue: MYC
Gene-model tissue-cancer distribution: Bubble Plot
Gene-drug pathway distribution
Pathways in MYC
| Database | Pathway ID | Pathway Des. |
|---|---|---|
| kegg | hsa04010 | MAPK signaling pathway - Homo sapiens (human) |
| kegg | hsa04012 | ErbB signaling pathway - Homo sapiens (human) |
| kegg | hsa04110 | Cell cycle - Homo sapiens (human) |
| kegg | hsa04151 | PI3K-Akt signaling pathway - Homo sapiens (human) |
| kegg | hsa04218 | Cellular senescence - Homo sapiens (human) |
| kegg | hsa04310 | Wnt signaling pathway - Homo sapiens (human) |
| kegg | hsa04350 | TGF-beta signaling pathway - Homo sapiens (human) |
| kegg | hsa04390 | Hippo signaling pathway - Homo sapiens (human) |
| kegg | hsa04550 | Signaling pathways regulating pluripotency of stem cells - Homo sapiens (human) |
| kegg | hsa04630 | Jak-STAT signaling pathway - Homo sapiens (human) |
| kegg | hsa04919 | Thyroid hormone signaling pathway - Homo sapiens (human) |
| kegg | hsa05161 | Hepatitis B - Homo sapiens (human) |
| kegg | hsa05166 | HTLV-I infection - Homo sapiens (human) |
| kegg | hsa05167 | Kaposi,s sarcoma-associated herpesvirus infection - Homo sapiens (human) |
| kegg | hsa05169 | Epstein-Barr virus infection - Homo sapiens (human) |
| kegg | hsa05200 | Pathways in cancer - Homo sapiens (human) |
| kegg | hsa05202 | Transcriptional misregulation in cancer - Homo sapiens (human) |
| kegg | hsa05205 | Proteoglycans in cancer - Homo sapiens (human) |
| kegg | hsa05206 | MicroRNAs in cancer - Homo sapiens (human) |
| kegg | hsa05210 | Colorectal cancer - Homo sapiens (human) |
| kegg | hsa05213 | Endometrial cancer - Homo sapiens (human) |
| kegg | hsa05216 | Thyroid cancer - Homo sapiens (human) |
| kegg | hsa05219 | Bladder cancer - Homo sapiens (human) |
| kegg | hsa05220 | Chronic myeloid leukemia - Homo sapiens (human) |
| kegg | hsa05221 | Acute myeloid leukemia - Homo sapiens (human) |
| kegg | hsa05222 | Small cell lung cancer - Homo sapiens (human) |
| kegg | hsa05224 | Breast cancer - Homo sapiens (human) |
| kegg | hsa05225 | Hepatocellular carcinoma - Homo sapiens (human) |
| kegg | hsa05226 | Gastric cancer - Homo sapiens (human) |
| kegg | hsa05230 | Central carbon metabolism in cancer - Homo sapiens (human) |
| netpath | Pathway_EGFR1 | EGFR1 |
| netpath | Pathway_TGF_beta_Receptor | TGF_beta_Receptor |
| reactome | R-HSA-1280215 | Cytokine Signaling in Immune system |
| reactome | R-HSA-1362277 | Transcription of E2F targets under negative control by DREAM complex |
| reactome | R-HSA-1538133 | G0 and Early G1 |
| reactome | R-HSA-157118 | Signaling by NOTCH |
| reactome | R-HSA-162582 | Signal Transduction |
| reactome | R-HSA-1640170 | Cell Cycle |
| reactome | R-HSA-1643685 | Disease |
| reactome | R-HSA-168256 | Immune System |
| reactome | R-HSA-170834 | Signaling by TGF-beta Receptor Complex |
| reactome | R-HSA-195721 | Signaling by WNT |
| reactome | R-HSA-1980143 | Signaling by NOTCH1 |
| reactome | R-HSA-201681 | TCF dependent signaling in response to WNT |
| reactome | R-HSA-201722 | Formation of the beta-catenin:TCF transactivating complex |
| reactome | R-HSA-2122947 | NOTCH1 Intracellular Domain Regulates Transcription |
| reactome | R-HSA-212436 | Generic Transcription Pathway |
| reactome | R-HSA-2173793 | Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer |
| reactome | R-HSA-2173796 | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription |
| reactome | R-HSA-2644602 | Signaling by NOTCH1 PEST Domain Mutants in Cancer |
| reactome | R-HSA-2644603 | Signaling by NOTCH1 in Cancer |
| reactome | R-HSA-2644606 | Constitutive Signaling by NOTCH1 PEST Domain Mutants |
| reactome | R-HSA-2894858 | Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer |
| reactome | R-HSA-2894862 | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants |
| reactome | R-HSA-392499 | Metabolism of proteins |
| reactome | R-HSA-4411364 | Binding of TCF/LEF:CTNNB1 to target gene promoters |
| reactome | R-HSA-449147 | Signaling by Interleukins |
| reactome | R-HSA-453279 | Mitotic G1-G1/S phases |
| reactome | R-HSA-5663202 | Diseases of signal transduction |
| reactome | R-HSA-5683057 | MAPK family signaling cascades |
| reactome | R-HSA-5687128 | MAPK6/MAPK4 signaling |
| reactome | R-HSA-5688426 | Deubiquitination |
| reactome | R-HSA-5689880 | Ub-specific processing proteases |
| reactome | R-HSA-597592 | Post-translational protein modification |
| reactome | R-HSA-6785807 | Interleukin-4 and Interleukin-13 signaling |
| reactome | R-HSA-69202 | Cyclin E associated events during G1/S transition |
| reactome | R-HSA-69206 | G1/S Transition |
| reactome | R-HSA-69242 | S Phase |
| reactome | R-HSA-69278 | Cell Cycle, Mitotic |
| reactome | R-HSA-69656 | Cyclin A:Cdk2-associated events at S phase entry |
| reactome | R-HSA-73857 | RNA Polymerase II Transcription |
| reactome | R-HSA-74160 | Gene expression (Transcription) |
| reactome | R-HSA-8864260 | Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors |
| reactome | R-HSA-8866911 | TFAP2 (AP-2) family regulates transcription of cell cycle factors |
| reactome | R-HSA-8878159 | Transcriptional regulation by RUNX3 |
| reactome | R-HSA-8939211 | ESR-mediated signaling |
| reactome | R-HSA-8951430 | RUNX3 regulates WNT signaling |
| reactome | R-HSA-9006931 | Signaling by Nuclear Receptors |
| reactome | R-HSA-9006936 | Signaling by TGF-beta family members |
| reactome | R-HSA-9018519 | Estrogen-dependent gene expression |
| biocarta | arfpathway | tumor suppressor arf inhibits ribosomal biogenesis |
| biocarta | cardiacegfpathway | role of egf receptor transactivation by gpcrs in cardiac hypertrophy |
| biocarta | cdmacpathway | cadmium induces dna synthesis and proliferation in macrophages |
| biocarta | ctcfpathway | ctcf: first multivalent nuclear factor |
| biocarta | erkpathway | erk1/erk2 mapk signaling pathway |
| biocarta | gleevecpathway | inhibition of cellular proliferation by gleevec |
| biocarta | mapkpathway | mapkinase signaling pathway |
| biocarta | p38mapkpathway | p38 mapk signaling pathway |
| biocarta | pparapathway | mechanism of gene regulation by peroxisome proliferators via ppara |
| biocarta | telpathway | telomeres telomerase cellular aging and immortality |
| biocarta | tertpathway | overview of telomerase protein component gene htert transcriptional regulation |
| biocarta | wntpathway | wnt signaling pathway |
| pid | ap1_pathway | AP-1 transcription factor network |
| pid | betacatenin_nuc_pathway | Regulation of nuclear beta catenin signaling and target gene transcription |
| pid | cd40_pathway | CD40/CD40L signaling |
| pid | ceramide_pathway | Ceramide signaling pathway |
| pid | cmyb_pathway | C-MYB transcription factor network |
| pid | e2f_pathway | E2F transcription factor network |
| pid | era_genomic_pathway | Validated nuclear estrogen receptor alpha network |
| pid | foxm1pathway | FOXM1 transcription factor network |
| pid | il2_1pathway | IL2-mediated signaling events |
| pid | il2_pi3kpathway | IL2 signaling events mediated by PI3K |
| pid | il2_stat5pathway | IL2 signaling events mediated by STAT5 |
| pid | il6_7pathway | IL6-mediated signaling events |
| pid | lkb1_pathway | LKB1 signaling events |
| pid | myc_activpathway | Validated targets of C-MYC transcriptional activation |
| pid | myc_pathway | C-MYC pathway |
| pid | myc_represspathway | Validated targets of C-MYC transcriptional repression |
| pid | notch_pathway | Notch signaling pathway |
| pid | p73pathway | p73 transcription factor network |
| pid | pdgfrbpathway | PDGFR-beta signaling pathway |
| pid | ps1pathway | Presenilin action in Notch and Wnt signaling |
| pid | smad2_3nuclearpathway | Regulation of nuclear SMAD2/3 signaling |
| pid | telomerasepathway | Regulation of Telomerase |
| pharmgkb | PA162356267 | EGFR Inhibitor Pathway, Pharmacodynamics |
| pharmgkb | PA165374494 | Busulfan Pathway, Pharmacodynamics |
| pharmgkb | PA165980050 | Vemurafenib Pathway, Pharmacodynamics |
| pharmgkb | PA165980050 | update your name in edit mode |
| smpdb | SMP02298 | Glutaminolysis and Cancer |
| wikipathways | WP127 | IL-5 Signaling Pathway |
| wikipathways | WP1530 | miRNA Regulation of DNA Damage Response |
| wikipathways | WP1545 | miRNAs involved in DNA damage response |
| wikipathways | WP1742 | TP53 Network |
| wikipathways | WP1971 | Integrated Cancer Pathway |
| wikipathways | WP1984 | Integrated Breast Cancer Pathway |
| wikipathways | WP2032 | Human Thyroid Stimulating Hormone (TSH) signaling pathway |
| wikipathways | WP2037 | Prolactin Signaling Pathway |
| wikipathways | WP205 | IL-7 Signaling Pathway |
| wikipathways | WP2064 | Neural Crest Differentiation |
| wikipathways | WP2203 | Thymic Stromal LymphoPoietin (TSLP) Signaling Pathway |
| wikipathways | WP2249 | Metastatic brain tumor |
| wikipathways | WP2263 | Androgen Receptor Network in Prostate Cancer |
| wikipathways | WP23 | B Cell Receptor Signaling Pathway |
| wikipathways | WP2363 | Gastric Cancer Network 2 |
| wikipathways | WP2431 | Spinal Cord Injury |
| wikipathways | WP2446 | Retinoblastoma (RB) in Cancer |
| wikipathways | WP254 | Apoptosis |
| wikipathways | WP2571 | Polycystic Kidney Disease Pathway |
| wikipathways | WP2586 | Aryl Hydrocarbon Receptor |
| wikipathways | WP2593 | JAK-STAT |
| wikipathways | WP2637 | Structural Pathway of Interleukin 1 (IL-1) |
| wikipathways | WP2720 | Signaling by NOTCH1 |
| wikipathways | WP2755 | Transcriptional activity of SMAD2-SMAD3-SMAD4 heterotrimer |
| wikipathways | WP2773 | Degradation of beta-catenin by the destruction complex |
| wikipathways | WP2804 | Hair Follicle Development- Induction (Part 1 of 3) |
| wikipathways | WP2815 | Mammary gland development pathway - Involution (Stage 4 of 4) |
| wikipathways | WP2828 | Bladder Cancer |
| wikipathways | WP2858 | Ectoderm Differentiation |
| wikipathways | WP2877 | Vitamin D Receptor Pathway |
| wikipathways | WP2878 | PPAR Alpha Pathway |
| wikipathways | WP2882 | Nuclear Receptors Meta-Pathway |
| wikipathways | WP3299 | let-7 inhibition of ES cell reprogramming |
| wikipathways | WP3303 | Rac1-Pak1-p38-MMP-2 pathway |
| wikipathways | WP3339 | TCF dependent signaling in response to WNT |
| wikipathways | WP3558 | Beta-catenin independent WNT signaling |
| wikipathways | WP363 | Wnt Signaling Pathway |
| wikipathways | WP3639 | Apoptotic Signaling Pathway |
| wikipathways | WP3640 | Imatinib and Chronic Myeloid Leukemia |
| wikipathways | WP3646 | Hepatitis C and Hepatocellular Carcinoma |
| wikipathways | WP3651 | Pathways Affected in Adenoid Cystic Carcinoma |
| wikipathways | WP366 | TGF-beta Signaling Pathway |
| wikipathways | WP3680 | Association Between Physico-Chemical Features and Toxicity Associated Pathways |
| wikipathways | WP382 | MAPK Signaling Pathway |
| wikipathways | WP3872 | Regulation of Apoptosis by Parathyroid Hormone-related Protein |
| wikipathways | WP399 | Wnt Signaling Pathway and Pluripotency |
| wikipathways | WP400 | p38 MAPK Signaling Pathway |
| wikipathways | WP4066 | Interleukin-4 and 13 signaling |
| wikipathways | WP4107 | Transcriptional regulation by RUNX3 |
| wikipathways | WP4141 | PI3K-AKT-mTOR - VitD3 Signalling |
| wikipathways | WP4155 | Endometrial cancer |
| wikipathways | WP4172 | PI3K-Akt Signaling Pathway |
| wikipathways | WP4216 | Chromosomal and microsatellite instability in colorectal cancer |
| wikipathways | WP428 | Wnt Signaling Pathway |
| wikipathways | WP45 | G1 to S cell cycle control |
| wikipathways | WP49 | IL-2 Signaling Pathway |
| wikipathways | WP61 | Notch Signaling Pathway |
| wikipathways | WP673 | ErbB Signaling Pathway |
| wikipathways | WP707 | DNA Damage Response |
| wikipathways | WP710 | DNA Damage Response (only ATM dependent) |
Gene-Drug: Aster Plot
| Drug ID | Drug Name | Model Num. |
|---|---|---|
| iGMDRD565 | BI-D1870 | 1 |
| iGMDRD68 | Paclitaxel | 1 |
| iGMDRD504 | Obatoclax | 1 |
| iGMDRD220 | fumonisin B1 | 1 |
| iGMDRD300 | Tozasertib | 8 |
| iGMDRD935 | JQ12 | 1 |
| iGMDRD412 | VX-702 | 1 |
| iGMDRD414 | MST-312 | 3 |
| iGMDRD1015 | THZ-2-102-1 | 1 |
| iGMDRD872 | BRD7137 | 3 |
| iGMDRD456 | Crizotinib | 1 |
| iGMDRD614 | Dabrafenib | 1 |
| iGMDRD262 | KU-55933 | 1 |
| iGMDRD382 | CEP-701 | 1 |
| iGMDRD607 | Ubistatin B | 3 |
| iGMDRD374 | Zibotentan (ZD4054) | 1 |
| iGMDRD351 | GW843682X | 3 |
| iGMDRD782 | DC-45-A2 | 3 |
| iGMDRD441 | TW 37 | 1 |
| iGMDRD388 | YM201636 | 1 |
| iGMDRD885 | Compound 110 | 6 |
| iGMDRD870 | BRD63610 | 1 |
| iGMDRD509 | NVP-BHG712 | 1 |
| iGMDRD491 | TAE-684 | 1 |
| iGMDRD255 | SB225002 | 16 |
| iGMDRD690 | PRIMA-1MET | 3 |
| iGMDRD131 | Erlotinib | 1 |
| iGMDRD598 | QS-11 | 2 |
| iGMDRD835 | BET inhibitor | 6 |
| iGMDRD312 | Pelitinib | 1 |
| iGMDRD63 | Camptothecin | 2 |
| iGMDRD328 | AR-42 | 1 |
| iGMDRD878 | CDK7 inhibitor | 2 |
| iGMDRD136 | Nutlin-3 | 1 |
| iGMDRD97 | Bexarotene | 1 |
| iGMDRD387 | CHIR-99021 | 2 |
| iGMDRD659 | Avagacestat (BMS-708163) | 1 |
| iGMDRD1008 | SR-II-138A | 3 |
| iGMDRD772 | BRD4770 | 3 |
| iGMDRD401 | Afatinib | 1 |
| iGMDRD608 | Refametinib | 1 |
| iGMDRD686 | PF4708671 | 1 |
| iGMDRD588 | HG-5-88-01 | 1 |
| iGMDRD193 | Fqi1 | 1 |
| iGMDRD163 | all trans Retinoic Acid | 2 |
| iGMDRD289 | Parthenolide | 1 |
| iGMDRD705 | Nakiterpiosin | 8 |
| iGMDRD655 | SCHEMBL618594 | 1 |
| iGMDRD173 | Epothilone B | 3 |
| iGMDRD286 | Nsc 632839 | 3 |
| iGMDRD329 | Merck60 | 6 |
| iGMDRD366 | PI-103 | 6 |
| iGMDRD532 | Olaparib | 2 |
| iGMDRD150 | RITA | 1 |
| iGMDRD909 | FACT inhibitor | 1 |
| iGMDRD48 | Dexamethasone | 3 |
| iGMDRD564 | GSK-650394 | 1 |
| iGMDRD330 | BRD4132 | 1 |
| iGMDRD945 | ML214 | 1 |
| iGMDRD49 | Mitomycin | 1 |
| iGMDRD376 | Tivozanib | 1 |
| iGMDRD541 | SNX-2112 (PF-04928473) | 1 |
| iGMDRD284 | Palbociclib | 2 |
| iGMDRD44 | Temozolomide | 3 |
| iGMDRD593 | CX-5461 | 1 |
| iGMDRD52 | Rotenone | 1 |
| iGMDRD294 | Batimastat | 3 |
| iGMDRD190 | Nilotinib | 1 |
| iGMDRD64 | Parbendazole | 1 |
| iGMDRD524 | ISX-9 | 1 |
| iGMDRD399 | Selumetinib | 3 |
| iGMDRD74 | Idarubicin | 1 |
| iGMDRD506 | Fedratinib | 1 |
| iGMDRD391 | OSU-03012 | 1 |
| iGMDRD780 | PP-30 | 3 |
| iGMDRD427 | ABT737 | 2 |
| iGMDRD781 | Sirolimus | 3 |
| iGMDRD126 | Tipifarnib | 7 |
| iGMDRD443 | Linifanib | 1 |
| iGMDRD988 | PIM inhibitor | 2 |
| iGMDRD107 | Valdecoxib | 2 |
| iGMDRD434 | BMS-536924 | 2 |
| iGMDRD267 | Oligomycin A | 3 |
| iGMDRD785 | XMD15-27 | 1 |
| iGMDRD179 | Shikonin | 1 |
| iGMDRD42 | Vorinostat | 1 |
| iGMDRD544 | Vismodegib (GDC-0449) | 1 |
| iGMDRD116 | CD437 | 10 |
| iGMDRD160 | Cis-Platin | 1 |
| iGMDRD424 | Tamatinib | 3 |
| iGMDRD652 | UNC0638 | 1 |
| iGMDRD463 | ZSTK 474 | 1 |
| iGMDRD307 | Manumycin A | 1 |
| iGMDRD792 | Cetuximab | 1 |
| iGMDRD512 | nutlin 3 | 1 |
| iGMDRD177 | Teniposide | 1 |
| iGMDRD132 | (-)-gallocatechin-3-O-gallate | 4 |
| iGMDRD85 | Ursolic acid | 1 |
| iGMDRD536 | PLX-4720 | 1 |
| iGMDRD309 | 17AAG | 1 |
| iGMDRD270 | Ciclosporin | 5 |
| iGMDRD138 | PX 12 | 1 |
| iGMDRD134 | Sorafenib | 1 |
| iGMDRD454 | JNK Inhibitor VIII | 1 |
| iGMDRD451 | Serdemetan | 3 |
| iGMDRD100 | Zebularine | 1 |
| iGMDRD887 | Compound 23 citrate | 3 |
| iGMDRD692 | SB590885 | 1 |
| iGMDRD144 | NSC95397 | 1 |
| iGMDRD494 | Neopeltolide | 1 |
| iGMDRD599 | Salermide | 1 |
| iGMDRD579 | PF750 | 3 |
| iGMDRD297 | Austocystin D | 1 |
| iGMDRD776 | QL-XI-92 | 1 |
| iGMDRD446 | LY 2183240 | 2 |
| iGMDRD253 | Vincaleukoblastine | 1 |
| iGMDRD498 | GW441756X | 1 |
| iGMDRD718 | Pyrvinium pamoate | 1 |
| iGMDRD737 | JNK-IN-2 | 1 |
| iGMDRD66 | Doxorubicin | 1 |
| iGMDRD455 | Idelalisib | 1 |
| iGMDRD213 | SMR000068650 | 1 |
| iGMDRD77 | Itraconazole | 8 |
| iGMDRD672 | Alectinib | 1 |
| iGMDRD103 | SN-38 | 3 |
| iGMDRD293 | Bleomycin | 2 |
| iGMDRD121 | GMX1778 | 1 |
| iGMDRD137 | Indisulam | 3 |
| iGMDRD147 | Prima-1 | 3 |
| iGMDRD264 | Bryostatin 1 | 1 |
| iGMDRD421 | AZD7762 | 1 |
| iGMDRD871 | BRD6368 | 1 |
| iGMDRD662 | JQ-1 | 1 |
| iGMDRD560 | MK-2206 | 1 |
| iGMDRD20 | Embelin | 1 |
| iGMDRD79 | Gemcitabine | 3 |
| iGMDRD475 | BX 912 | 1 |
| iGMDRD123 | Isoevodiamine | 3 |
| iGMDRD154 | NSC23766 | 2 |
| iGMDRD775 | NCGC00346967-01 | 1 |
| iGMDRD352 | PD-0325901 | 1 |
| iGMDRD237 | ABT-751 | 3 |
| iGMDRD187 | BRD9876 | 3 |
| iGMDRD992 | QL-VIII-58 | 1 |
| iGMDRD23 | Gossypol | 1 |
| iGMDRD133 | Lapatinib | 1 |
| iGMDRD543 | GDC-0449 | 1 |
| iGMDRD730 | Kahalalide F | 6 |
| iGMDRD888 | Compound 44 | 5 |
| iGMDRD670 | ML 210 | 1 |
| iGMDRD546 | BMS-754807 | 6 |
| iGMDRD483 | SCH-529074 | 1 |
| iGMDRD409 | Saracatinib | 1 |
| iGMDRD889 | Compound 7d-cis | 3 |
| iGMDRD654 | SL 0101-1 | 1 |
| iGMDRD425 | ERASTIN | 4 |
| iGMDRD466 | Chaetocin | 3 |
| iGMDRD679 | Bistramide A | 8 |
| iGMDRD639 | YK 4-279 | 4 |
| iGMDRD748 | PHA-665752 | 1 |
| iGMDRD61 | Kinetin riboside | 1 |
Gene in drug-gene network: Network Plot
Gene-drug targets distribution
Gene Structure: PDB
Models in MYC
CLASSFICATION
Copyright © 2018 Modellab | All Rights Reserved
Disclaimer: iGMDR is intended for research purposes only. Its information cannot be used for emergencies or medical or professional advice.